Search Results

Up to $2.5 million in funding from NIH will be used to develop TIMING™ kits for manufacturing analytics that provide end-users with rapid

Beactica Therapeutics AB, the Swedish precision oncology company, announced that it has entered into a research collaboration agreement with the National Center for Advancing Translational Sciences, one of 27 institutes and centers at the U.S. National Institutes of Health.

On May 23, OBiO Technology, a world leading contract development and manufacturing organization for cell and gene therapy, officially launched the “Center for Clinical Evaluation and Translation of Advanced Therapies for Pediatric Rare and Genetic Diseases” at the 2024 Global Rare Disease Research Symposium and the 2nd China Rare Disease Research and Translational Medicine Conference.

Astellas Pharma’s new life sciences center houses its first U.S.-based SakuLab, an incubator space for external partners, as well as its engineered small molecules unit.

Curi Bio proudly announces two recent SBIR grants worth $4.4 million from the National Institutes of Health to support its pioneering work on implementing human models to advance discovery of the next generation of medicines.

SHEPHERD Therapeutics, a company dedicated to catalyzing lifesaving treatments for rare cancer patients, today announced a collaboration with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH).

Friday’s agenda highlighted some of the pivotal translational studies, as well as the researchers who are making breakthroughs in genetic therapies.

Factor Bioscience Inc. today announced the addition of three members to its translational science team, which will be led by Kyle Garland, Ph.D., who joins Factor as Director of Translational Science.